Valuation: Cerenis Therapeutics

Market Cap 67.76M 77.34M 62.91M 57.81M 109M 7.46B 111M 749M 293M 3.65B 290M 284M 12.61B P/E 2026 *
-4.13x
P/E 2027 * -6.48x
Enterprise Value 73.56M 83.96M 68.29M 62.75M 118M 8.1B 120M 814M 318M 3.96B 315M 308M 13.69B EV / Sales 2026 *
15.8x
EV / Sales 2027 * 5.22x
Free-Float
82.07%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 49 2019-09-05
Director of Finance/CFO - -
Chief Operating Officer - 2005-12-31
Director TitleAgeSince
Director/Board Member 49 2019-09-05
Director/Board Member 52 2010-07-19
Director/Board Member 76 2015-02-05
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 77.34M
-0.43%-4.26%+52.09%+85.69% 55.27B
+3.98%+5.07%+61.35%+64.59% 54.15B
-1.82%-2.89%+3.61%+405.88% 23.11B
-0.54%-0.17%-17.60%-15.43% 23.22B
+1.03%-0.20%+36.49%-3.23% 20.33B
-1.67%-0.50%+29.77%-30.18% 17.91B
+0.87%-0.19%+39.07%+553.51% 15.76B
+0.43%-10.61%+175.63%+299.61% 15B
-2.03%-1.03%+23.63%+179.23% 13.82B
Average -0.04%-1.65%+44.89%+171.07% 26.51B
Weighted average by Cap. +0.48%-1.05%+44.96%+135.58%

Financials

2026 *2027 *
Net sales 4.66M 5.32M 4.33M 3.98M 7.49M 513M 7.6M 51.53M 20.17M 251M 19.96M 19.53M 867M 14.72M 16.8M 13.66M 12.55M 23.66M 1.62B 24.01M 163M 63.7M 793M 63.05M 61.69M 2.74B
Net income -19.83M -22.63M -18.41M -16.91M -31.87M -2.18B -32.34M -219M -85.82M -1.07B -84.94M -83.11M -3.69B -12.92M -14.75M -12M -11.02M -20.77M -1.42B -21.08M -143M -55.93M -696M -55.36M -54.17M -2.41B
Net Debt 5.8M 6.62M 5.38M 4.95M 9.32M 639M 9.46M 64.14M 25.11M 313M 24.85M 24.31M 1.08B 9M 10.27M 8.36M 7.68M 14.47M 991M 14.68M 99.53M 38.96M 485M 38.56M 37.73M 1.68B
Logo Cerenis Therapeutics
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2025, the company boasted a portfolio of 3 products in clinical development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.920EUR
Average target price
10.50EUR
Spread / Average Target
+446.88%

Annual profits - Rate of surprise